ArsenalBio raises $220M Series B to advance cell‑therapy cancer therapeutics

In 2022, ArsenalBio announced a $220M Series B round, one of the largest cell‑therapy financings of the year, with participation from SoftBank Vision Fund, Bristol Myers Squibb and Westlake Village BioPartners. The round brings the company’s total raised capital to $305M since its 2019 founding.

The funds will advance ArsenalBio’s lead drug candidate targeting ovarian cancer toward FDA clearance and support broader pipeline expansion, positioning the firm to capitalize on the growing cell‑therapy market.

$220M Series B, total $305M funding, progress toward FDA clearance for ovarian‑cancer therapeutic

Investors see strong therapeutic potential in cell‑based approaches, prompting sizable commitments to ArsenalBio’s platform.

The capital enables costly clinical‑trial activities, manufacturing scale‑up and regulatory‑submission work.

Early progress on an ovarian‑cancer asset de‑risks the technology and attracts further partnership interest.

In a hot biotech niche, securing large late‑stage private capital can accelerate product development and de‑risk the path to regulatory approval.

With the new financing, ArsenalBio advanced preclinical studies, filed IND‑enabling documentation and moved toward clinical trials for its ovarian‑cancer candidate, while exploring additional indications.